Elabscience

Recombinant Mouse TNFRSF17/BCMA Protein (His & Fc Tag)(Active)

Product Code:
 
PKSM040938
Product Group:
 
Recombinant Proteins
Supplier:
 
Elabscience
Host Type:
 
Mouse
Regulatory Status:
 
RUO
Application:
 
Enzyme-Linked Immunosorbent Assay (ELISA)
Shipping:
 
This product is provided as lyophilized powder which is shipped with ice packs.
Storage:
 
Generally lyophilized proteins are stable for up to 12 months when stored at -20 to -80°C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of reconstituted samples are stable at < -20°C for 3 months.
 

No additional charges, what you see is what you pay! *

CodeSizePrice
PKSM040938-100ug100ug£664.00
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: China.
Typical lead time: 14-21 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • Show All

Further Information

Abbreviation:
TNFRSF17;BCMA
Accession:
NP_035738.1
Activity:
Immobilized human BAFF at 10 ug/ml (100 ul/well) can bind mouse BCMA-Fch, The EC50 of mouse BCMA-Fch is 0.02-0.06 ug/mL.
Background:
Tumor necrosis factor receptor superfamily, member 17 (TNFRSF17), also known as B cell maturation antigen (BCMA) or CD269 antigen, is a member of the TNF-receptor superfamily. This receptor is preferentially expressed in mature B lymphocytes, and may be important for B cell development and autoimmune response. This receptor has been shown to specifically bind to the tumor necrosis factor (ligand) superfamily, member 13b (TNFSF13BBAFF), and to lead to NF-kappaB and MAPK8/JNK activation. TNFRSF17/BCMA/CD269 also binds to various TRAF family members, and thus may transduce signals for cell survival and proliferation. TNFRSF17/BCMA/CD269 is a receptor for TALL-1 and BCMA activates NF-kappaB through a TRAF5-, TRAF6-, NIK-, and IKK-dependent pathway. The identification of TNFRSF17 as a NF-kappaB-activating receptor for TALL-1 suggests molecular targets for drug development against certain immunodeficient or autoimmune diseases. TNFRSF17/BCMA is a target of donor B-cell immunity in patients with myeloma who respond to DLI. Antibody responses to cell-surface BCMA may contribute directly to tumor rejection in vivo.
Calculated MW:
33.7 kDa
Endotoxin:
< 1.0 EU per ug of the protein as determined by the LAL method.
Expression Host:
HEK293 Cells
Formulation:
Lyophilized from sterile PBS, pH 7.4
Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization.
Please refer to the specific buffer information in the printed manual.
Fusion tag:
C-His-Fc
ObservedMW:
35-48 kDa
Purity:
> 90 % as determined by reducing SDS-PAGE.
Sequence:
Met 1-Thr 49
Target Synonym:
Tumor necrosis factor receptor superfamily member 17;B-cell maturation protein;CD269;Tnfrsf17;BCM;BCMA;Tnfrsf13;Tnfrsf13a

Documents